2022
Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2021
Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy
Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy. European Radiology 2021, 31: 8858-8867. PMID: 34061209, PMCID: PMC8848338, DOI: 10.1007/s00330-021-08058-7.Peer-Reviewed Original ResearchConceptsColorectal cancer liver metastasesCancer liver metastasesTotal tumor volumeIntra-arterial therapyTotal liver volumeLiver metastasesTumor volumeTumor burdenTumor diameterPatient survivalBaseline MRILiver volumeMultivariable Cox proportional hazards modelsKaplan-Meier survival curvesWhole liverCox proportional hazards modelKaplan-Meier methodPrognostic staging systemSurvival of patientsColorectal cancer metastasisMethodsThis retrospective studyPre-treatment MRIProportional hazards modelAppropriate cutoff valueHR 1.7Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma
Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Scientific Reports 2021, 11: 9337. PMID: 33927226, PMCID: PMC8085245, DOI: 10.1038/s41598-021-88426-x.Peer-Reviewed Original ResearchConceptsTotal tumor volumeConventional transarterial chemoembolizationTumor diameterIntrahepatic cholangiocarcinomaOverall survivalTumor areaICC patientsTumor volumeHigh tumor burden groupTumor analysisOS of patientsHazard ratioTransarterial chemoembolizationTumor burdenBurden groupConventional chemoembolizationHTB groupRetrospective analysisPatientsSurvival curvesMultivariate analysisChemoembolizationCholangiocarcinomaETVBaseline images
2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved responseProspective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies
Savic LJ, Chapiro J, Funai E, Bousabarah K, Schobert IT, Isufi E, Geschwind JH, Stark S, He P, Rudek MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. European Radiology 2020, 31: 3002-3014. PMID: 33063185, DOI: 10.1007/s00330-020-07380-w.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationProspective clinical trialsTumor responseConventional TACEAdverse eventsTransarterial chemoembolizationLiver malignanciesClinical trialsMarker predictiveTumor volumeExact testChild-Pugh B classVolumetric tumor responseChild-Pugh BPeak concentrationNon-compartmental analysisFisher's exact testDose normalizationQuantitative European AssociationStandard non-compartmental analysisTime-concentration curveLiver criteriaLobar distributionDoxorubicin pharmacokineticsNeuroendocrine metastasesQuantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma
Auer TA, Della Seta M, Collettini F, Chapiro J, Zschaeck S, Ghadjar P, Badakhshi H, Florange J, Hamm B, Budach V, Kaul D. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma. Acta Radiologica 2020, 62: 1200-1207. PMID: 32938221, DOI: 10.1177/0284185120953796.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survivalTumor volumeGlioblastoma multiformeMagnetic resonance imagingMultivariable analysisCommon malignant primary brain tumorIntracranial progression-free survivalKarnofsky performance status scoreCranial magnetic resonance imagingMalignant primary brain tumorMedian overall survivalPerformance status scoreOS of patientsCox regression modelSignificant prognostic rolePrimary brain tumorsContrast-enhanced MRI sequencesQuantitative volumetric assessmentResection statusPrognostic roleMethyltransferase statusWorse prognosisEntire cohortNon-invasive methodQuantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation
Tegel BR, Huber S, Savic LJ, Lin M, Gebauer B, Pollak J, Chapiro J. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation. Acta Radiologica 2020, 61: 1708-1716. PMID: 32216452, PMCID: PMC7529766, DOI: 10.1177/0284185120909964.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellContrast MediaDisease ProgressionFemaleHumansImaging, Three-DimensionalKidney NeoplasmsMaleMiddle AgedNeoplasm StagingRadiography, InterventionalRetrospective StudiesSensitivity and SpecificityTumor BurdenUltrasonography, InterventionalConceptsProgression-free survivalTotal tumor volumeRenal cell carcinomaCell carcinomaOdds ratioTumor volumeImaging biomarkersImage-guided thermal ablationPrognosis of patientsRENAL nephrometry scoreCox regression modelLargest tumor diameterLog-rank testKaplan-Meier plotsCross-sectional imagingSensitive imaging biomarkerMetastatic diseaseSecondary outcomesPrimary outcomeDistant metastasisNephrometry scoreTumor diameterOutcome parametersLesion vascularityTNM stage
2019
Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?
Luedemann WM, Geisel D, Gebauer B, Schnapauff D, Chapiro J, Wieners G, Steffen I, Kahn J. Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT? European Radiology 2019, 30: 1601-1608. PMID: 31811428, DOI: 10.1007/s00330-019-06430-2.Peer-Reviewed Original ResearchConceptsLipiodol depositionNative CT scansTumor volumeTumour vascularisationTechnical successHCC patientsCE-CTCT scanDifferent imaging modalitiesImaging modalitiesContrast-enhanced CTContrast-enhanced MRPearson correlation coefficientBaseline imagingSubgroup analysisRespective regression coefficientsCT groupLinear regression analysisCE-MRICE-MRVascularisationCTContrast phasesPatientsCTACETheranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model
van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019, 9: 3674-3686. PMID: 31281506, PMCID: PMC6587357, DOI: 10.7150/thno.32943.Peer-Reviewed Original ResearchConceptsOil Red OPerfusion indexMicrovascular densityLipiodol depositionLiver cancerTherapeutic efficacyVX2 tumorsContrast-enhanced CT scanRabbit liver tumor modelTumor-specific functionsNon-tumoral liverLiver tumor modelRadiological-pathological correlationVX2 rabbit liver tumor modelPortal flowTransarterial chemoembolizationLeft lobeLipiodol retentionTherapeutic managementPatient responseTumor vascularityTumor volumeArterial flowCT scanTumor perfusionA 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis
Della Seta M, Collettini F, Chapiro J, Angelidis A, Engeling F, Hamm B, Kaul D. A 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis. Acta Radiologica 2019, 60: 1496-1503. PMID: 30841703, DOI: 10.1177/0284185119831692.Peer-Reviewed Original ResearchConceptsIntracranial progression-free survivalSingular brain metastasisStereotactic radiation therapyPre-treatment magnetic resonance imagingMagnetic resonance imagingBrain metastasesPrognostic factorsTumor volumeRadiation therapyCranial magnetic resonance imagingContrast-enhanced MRI scansMultivariable Cox regressionProgression-free survivalIntracranial malignant tumorPrediction of survivalOverall survivalMultivariable analysisPrognostic indexCox regressionRetrospective studyMalignant tumorsQuantitative imaging biomarkersMRI scansPatientsRadiomic biomarkersQuantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization
Schobert I, Chapiro J, Nezami N, Hamm CA, Gebauer B, Lin M, Pollak J, Saperstein L, Schlachter T, Savic LJ. Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization. Journal Of Nuclear Medicine 2019, 60: 1066-1072. PMID: 30655331, PMCID: PMC6681698, DOI: 10.2967/jnumed.118.219691.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiographyBiomarkersCarcinoma, HepatocellularEmbolization, TherapeuticFeasibility StudiesFemaleHumansImaging, Three-DimensionalLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMicrospheresMiddle AgedMultimodal ImagingPrognosisRegression AnalysisRetrospective StudiesTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsNon-HCC patientsTransarterial radioembolizationHepatocellular carcinomaBaseline imagingTumor responseTumor volumeChild-Pugh class B patientsBaseline imaging featuresClass B patientsNormal liver ratiosTotal tumor volumeSPECT/CTContrast-enhanced MRIQuantitative European AssociationMultiphasic contrast-enhanced MRIInstitutional review boardHigh TNRPreprocedural MRIChild-PughB patientsLiver criteriaTumor burdenClinical parametersHepatic malignanciesRetrospective study
2016
Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis
Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Marshall K, Lin M, Gebauer B, Chapiro J, Salem R, Geschwind JF. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Translational Oncology 2016, 9: 377-383. PMID: 27641641, PMCID: PMC5021812, DOI: 10.1016/j.tranon.2016.07.005.Peer-Reviewed Original ResearchRenal cell carcinomaOverall survivalIntraarterial therapyMagnetic resonance imagingTumor responseTumor volumeMetastatic renal cell carcinomaRenal cell carcinoma metastaticCox proportional hazards modelEarly response assessmentMedian overall survivalResponse Evaluation CriteriaKaplan-Meier curvesLog-rank testCourse of diseaseProportional hazards modelQuantitative European AssociationOnly significant predictorWorld Health OrganizationRCC metastaticCarcinoma metastaticLiver metastasesCell carcinomaSurrogate markerTreatment response3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival
Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. European Radiology 2016, 26: 3243-3252. PMID: 26762942, PMCID: PMC4942412, DOI: 10.1007/s00330-015-4168-3.Peer-Reviewed Original ResearchConceptsHazard ratioOverall survivalTransarterial chemoembolizationBaseline MRIHepatocellular carcinomaTumor burdenDominant lesionTumor assessmentTumor volumeMultivariate cox proportional hazard ratiosCox proportional hazard ratiosCurrent radiological methodMethodsThis retrospective analysisProportional hazard ratiosBCLC staging systemKaplan-Meier plotsTumor diameterPatient survivalStaging systemHCC patientsMultiple lesionsLiver volumeRetrospective analysisLesion assessmentPatients
2015
3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma
Schneider T, Chapiro J, Lin M, Geschwind JF, Kleinberg L, Rigamonti D, Jusué-Torres I, Marciscano AE, Yousem DM. 3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. European Radiology 2015, 26: 849-857. PMID: 26139318, PMCID: PMC4698362, DOI: 10.1007/s00330-015-3895-9.Peer-Reviewed Original ResearchConceptsSingle-session stereotactic radiosurgeryTotal tumor volumeSignificant tumor shrinkageVestibular schwannomaTumor shrinkageStereotactic radiotherapyTumor volumeRadiation therapyStereotactic radiosurgeryT1-weighted contrast-enhanced MRISubsequent microsurgical resectionTumor-related symptomsSporadic vestibular schwannomaContrast-enhanced MRIFSRT groupRadiological progressionMicrosurgical resectionClinical outcomesSRS groupRetrospective analysisResponse assessmentPatientsVolumetric assessmentFSRTSchwannomaIntraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, Geschwind JF. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. CardioVascular And Interventional Radiology 2015, 38: 1548-1556. PMID: 26001366, PMCID: PMC4651808, DOI: 10.1007/s00270-015-1129-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyContrast MediaEthiodized OilFemaleFollow-Up StudiesHumansImage EnhancementImaging, Three-DimensionalLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsLipiodol depositionConventional transarterial chemoembolizationTumor responseOverall tumor volumeTumor volumeCE-MRIHepatocellular carcinomaTransarterial chemoembolizationTumor necrosisContrast-enhanced magnetic resonance imagingNecrotic tumour volumeResponse Evaluation CriteriaT-testMagnetic resonance imagingStudent's t-testMethodsThis IRBTarget lesionsRetrospective analysisSolid tumorsResonance imagingSpearman rank-order correlationPatientsCone-beam CTCBCTChemoembolization
2014
Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers
Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non–three-dimensional Imaging Markers. Radiology 2014, 275: 438-47. PMID: 25531387, PMCID: PMC4409467, DOI: 10.1148/radiol.14141180.Peer-Reviewed Original ResearchConceptsUnresectable hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaTumor diameterHazard ratioTumor responseTumor volumeResponse rateCox proportional hazard ratiosStaging markersTumor response rateProportional hazard ratiosResponse Evaluation CriteriaSurvival of patientsKaplan-Meier analysisSingle-institution analysisBaseline magnetic resonance imagesHigh response rateInstitutional review boardOverall survivalLiver (EASL) guidelinesPatient cohortImaging markerRadiologic measurementsLarge lesionsUveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization
Duran R, Chapiro J, Frangakis C, Lin M, Schlachter TR, Schernthaner RE, Wang Z, Savic LJ, Tacher V, Kamel IR, Geschwind JF. Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization. Translational Oncology 2014, 7: 447-455. PMID: 24953419, PMCID: PMC4202794, DOI: 10.1016/j.tranon.2014.05.004.Peer-Reviewed Original ResearchFirst transarterial chemoembolizationEarly tumor responseTransarterial chemoembolizationWorld Health OrganizationOverall survivalTumor responseTarget lesionsTumor volumeTumor enhancementUveal melanomaContrast-enhanced magnetic resonance imagingNon-target lesionsUveal melanoma metastaticMedian overall survivalResponse Evaluation CriteriaKaplan-Meier methodLog-rank testMetastatic uveal melanomaMagnetic resonance imagingMelanoma metastaticSurrogate biomarkerSolid tumorsResonance imagingResponse criteriaLesions